[go: up one dir, main page]

AR022974A1 - Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble. - Google Patents

Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble.

Info

Publication number
AR022974A1
AR022974A1 ARP000101208A ARP000101208A AR022974A1 AR 022974 A1 AR022974 A1 AR 022974A1 AR P000101208 A ARP000101208 A AR P000101208A AR P000101208 A ARP000101208 A AR P000101208A AR 022974 A1 AR022974 A1 AR 022974A1
Authority
AR
Argentina
Prior art keywords
cilostazol
drug
absorption
improve
preparation
Prior art date
Application number
ARP000101208A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR022974A1 publication Critical patent/AR022974A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparacion de cilostazol que comprende incorporar un polvo fino de cilostazol en un agente dispersante y/o solubilizante para mejorar de este modo ladispersibilidad y/o solubilidad. Además se proporciona un proceso para mejorar la absorcion de unad roga ligeramente soluble como el cilostazol incluso enla porcion inferior del tracto digestivo, en donde resulta difícil la absorcion de dicha droga en la porcion inferior del tracto digestivo cuando se utiliza unmétodo convencional. El cilostazolse absorbe de manera suficiente incluso en la porcion inferior del tracto digestivo para tener efecto como drogatrombolítica, una droga mejoradora de la circulacion cerebral o similares.
ARP000101208A 1999-03-25 2000-03-17 Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble. AR022974A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8136399 1999-03-25
JP27914799 1999-09-30

Publications (1)

Publication Number Publication Date
AR022974A1 true AR022974A1 (es) 2002-09-04

Family

ID=26422384

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101208A AR022974A1 (es) 1999-03-25 2000-03-17 Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble.

Country Status (15)

Country Link
US (1) US7144585B1 (es)
EP (1) EP1162973B1 (es)
JP (1) JP2011063611A (es)
AR (1) AR022974A1 (es)
AT (1) ATE296100T1 (es)
AU (1) AU781881B2 (es)
CA (1) CA2368626C (es)
DE (1) DE60020343T2 (es)
EG (1) EG23951A (es)
ES (1) ES2238994T3 (es)
HK (1) HK1041649B (es)
MY (1) MY131255A (es)
PT (1) PT1162973E (es)
TW (1) TWI263507B (es)
WO (1) WO2000057881A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006343445B8 (en) * 1998-11-02 2011-06-16 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
US20030045547A1 (en) 2001-05-02 2003-03-06 Shinji Aki Process for producing carbostyril derivatives
EP1300160B1 (en) * 2000-05-24 2014-03-12 Otsuka Pharmaceutical Co., Ltd. Method of stabilizing preparation
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
US7399864B2 (en) 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
US20050101631A1 (en) 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
WO2004066981A1 (en) * 2003-01-29 2004-08-12 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
GB0418791D0 (en) 2004-08-23 2004-09-22 Glaxo Group Ltd Novel process
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
KR100667367B1 (ko) * 2005-05-10 2007-01-10 충남대학교산학협력단 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법
US20090297596A1 (en) * 2005-05-23 2009-12-03 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
KR101697833B1 (ko) * 2005-12-22 2017-01-18 오츠카 세이야쿠 가부시키가이샤 약물 함유 왁스 매트릭스 입자의 제조 방법, 상기 방법에 사용되는 익스트루더, 및 실로스타졸을 함유하는 서방성 제제
US20070196399A1 (en) * 2006-02-21 2007-08-23 Shin-Etsu Chemical Co., Ltd. Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8519120B2 (en) 2006-08-08 2013-08-27 Shin-Etsu Chemical Co., Ltd. Methods for producing a low-substituted hydroxypropylcellulose powder
US8343547B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
KR20080076440A (ko) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2481398A4 (en) 2009-09-23 2013-03-06 Korea United Pharm Inc RETARD CILOSTA TOLL VEHICLE WITH IMPROVED ELUTION RATE AND MINIMAL SIDE EFFECTS
HUE035763T2 (en) 2010-06-08 2018-05-28 Kobe Gakuin Educational Found Method of producing coated particles and coated particles
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
KR20130106456A (ko) * 2011-04-29 2013-09-30 한국유나이티드제약 주식회사 약물 방출제어용 조성물
ES2422657B1 (es) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Composición farmacéutica sólida de cilostazol
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
KR101748215B1 (ko) * 2015-05-29 2017-06-20 한국유나이티드제약 주식회사 경구용 서방성 제제
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
JP7674080B2 (ja) * 2019-08-07 2025-05-09 沢井製薬株式会社 アビラテロン酢酸エステル含有製剤
KR20230116831A (ko) * 2020-11-30 2023-08-04 에스에스 세야쿠 가부시키 가이샤 이부프로펜을 함유하는 고형 제제
CN114533690B (zh) * 2022-03-22 2023-03-21 许昌市中心医院 含抗凝血药物西洛他唑的新制剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US5624683A (en) 1986-08-06 1997-04-29 Eisai Co., Ltd. Sustained-release multi-granule tablet
JPS63112519A (ja) * 1986-10-28 1988-05-17 Shin Etsu Chem Co Ltd ニフエジピン製剤の製造方法
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2764274B2 (ja) * 1988-03-28 1998-06-11 株式会社ミドリ十字 医薬組成物
JP2871776B2 (ja) * 1989-03-28 1999-03-17 カロライナ メディカル プロダクツ インコーポレイテッド スピロノラクトン組成物
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FI93924C (fi) 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
WO1993005770A1 (fr) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation a longue duree d'action
WO1994006414A1 (fr) 1992-09-18 1994-03-31 Yamanouchi Pharmaceutical Co., Ltd. Preparation d'hydrogel a liberation prolongee
JP3681185B2 (ja) * 1994-03-31 2005-08-10 太田製薬株式会社 錠剤製造用ニフェジピン固体粒子組成物
JPH07291869A (ja) 1994-04-26 1995-11-07 Otsuka Pharmaceut Factory Inc 経口投与用製剤
CN1128497A (zh) * 1994-05-17 1996-08-07 株式会社大塚制药工场 在血液的体外循环中防止血液凝固的方法及所应用的抗血栓性药物释放装置
JPH0873354A (ja) * 1994-09-07 1996-03-19 Otsuka Pharmaceut Co Ltd 気道過敏症および／または気道障害の予防、治療剤
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
WO1996021448A1 (en) * 1995-01-10 1996-07-18 Otsuka Pharmaceutical Co., Ltd. Resin particle, medical material and pharmaceutical preparation containing said resin particle
JP3799093B2 (ja) * 1995-01-10 2006-07-19 大塚製薬株式会社 樹脂粒状物およびこれを含有する医療製剤
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
AUPN651895A0 (en) * 1995-11-10 1995-12-07 Down Hole Technologies Pty Ltd Spear head assembly
JPH1067657A (ja) 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
AU2976897A (en) * 1996-06-18 1998-01-07 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
JPH1077234A (ja) * 1996-09-05 1998-03-24 Ohara Yakuhin Kogyo Kk 経口用固形製剤及びその製造方法
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
US6825214B2 (en) * 2000-08-14 2004-11-30 Teva Pharmaceutical Industries, Ltd. Substantially pure cilostazol and processes for making same
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions

Also Published As

Publication number Publication date
PT1162973E (pt) 2005-08-31
HK1041649B (en) 2005-11-04
US7144585B1 (en) 2006-12-05
TWI263507B (en) 2006-10-11
ES2238994T3 (es) 2005-09-16
EP1162973A1 (en) 2001-12-19
ATE296100T1 (de) 2005-06-15
AU3196500A (en) 2000-10-16
DE60020343D1 (de) 2005-06-30
JP2011063611A (ja) 2011-03-31
WO2000057881A1 (en) 2000-10-05
EP1162973B1 (en) 2005-05-25
HK1041649A1 (en) 2002-07-19
EG23951A (en) 2008-01-29
AU781881B2 (en) 2005-06-16
DE60020343T2 (de) 2006-01-26
CA2368626C (en) 2010-02-16
CA2368626A1 (en) 2000-10-05
MY131255A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
AR022974A1 (es) Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble.
NZ541593A (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
ATE350013T1 (de) Nanopartikelzusammensetzungen enthaltend insulin
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
DE60203260D1 (de) Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
NO20014662D0 (no) Fremgangsmåter og preparater for behandling av faste tumorer
DK1196146T3 (da) Pulverpartikler med glat overflade til anvendelse i inhalationsterapi
NZ621449A (en) Treatment with anti-vegf antibodies
MXPA05007158A (es) Formulacion farmaceutica con un agente activo insoluble.
KR940013541A (ko) 멸균시 입자응집을 막기위해 정제된 표면개질제를 사용하는 방법
DE69915733D1 (de) Kosmetische oder pharmazeutische Zusammensetzung in Form eines Feststoffs, welche verformt werden kann
NO20005625L (no) Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
PE20030323A1 (es) Composicion farmaceutica
WO2002056835A3 (en) Anticancer treatment using triptolide prodrugs
BRPI0516265A (pt) composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
CO5241299A1 (es) Aparato y metodo para administrar una pulverizacion medicinal
SV2003001098A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
EA200200313A1 (ru) Применение доцетаксела для лечения печеночно-клеточного рака
WO2007149586A3 (en) Anti-c35 antibodies for treating cancer
IS2171B (is) Samsetning sem eykur hreyfanleika
CN106214650A (zh) 一种伏立康唑分散片及其制备方法
WO2005007129A3 (en) Topical formulations with bioactive components